Table 2.

Summary of all adverse events reported by investigators in patients treated by nintedanib + pembrolizumab

Nintedanib dose	Grade 1–2		Grade 3–4
	150 mg BID	200 mg BID	150 mg BID	200 mg BID
Alanine aminotransferase increased	1 (16.7%)	1 (16.7%)	0	3 (50%)
Aspartate aminotransferase increased	1 (16.7%)	0	0	2 (33%)
Diarrhea	3 (50%)	1 (16.7%)	0	0
Hypothyroidism	2 (33%)	1 (16.7%)	0	0
Nausea	2 (33%)	1 (16.7%)	0	0
Vomiting	2 (33%)	1 (16.7%)	0	0
GGT increased	0	1 (16.7%)	0	1 (16.7%)
Fatigue	1 (16.7%)	1 (16.7%)	0	0
Abdominal pain	1 (16.7%)	1 (16.7%)	0	0
Decreased appetite	2 (33%)	0	0	0
Cutaneous rash	2 (33%)	0	0	0
Hypertension	1 (16.7%)	0	0	0
Venous thromboembolism	0	0	1 (16.7%)	0
Colitis	1 (16.7%)	0	0	0
Creatinin increased	0	1 (16.7%)	0	0
Dyspnea	0	1 (16.7%)	0	0
Headache	0	1 (16.7%)	0	0
Hearing impairment	0	1 (16.7%)	0	0
Hyperthyroidism	1 (16.7%)	0	0	0
Mucositis	1 (16.7%)	0	0	0
Nervous system disorder	0	1 (16.7%)	0	0
Peripheral motor neuropathy	1 (16.7%)	0	0	0
Platelet count decreased	1 (16.7%)	0	0	0
Renal and urinary disorder	0	1 (16.7%)	0	0
Supraventricular tachycardia	1 (16.7%)	0	0	0
Weight loss	1 (16.7%)	0	0	0